The common promoter polymorphism rs11666254 downregulates FPR2/ALX expression and increases risk of sepsis in patients with severe trauma

Abstract

BackgroundFormyl peptide receptor 2-lipoxin receptor (FPR2/ALX) modulates the anti-inflammatory response and therefore may be a target for treating sepsis. The purpose of this study was to investigate the association between genetic variants of the FPR2/ALX gene and sepsis after severe trauma as well as to further analyze the functions of sepsis-related genetic polymorphisms.MethodsThree tag single-nucleotide polymorphisms (tag SNPs) that captured all common alleles across the FPR2/ALX genomic region were genotyped using pyrosequencing in an initial sample consisting of 275 patients with severe trauma. The rs11666254 polymorphism, which had statistical significance, was genotyped in an additional 371 patients, and logistic regression analysis was performed to determine associations between the FPR2/ALX gene polymorphism and sepsis susceptibility after severe trauma. The messenger RNA (mRNA) and protein levels of FPR2/ALX in the lipopolysaccharide-stimulated white blood cells of trauma patients were determined by performing quantitative polymerase chain reactions and Western blot analysis. Tumor necrosis factor (TNF)-α production was measured by enzyme-linked immunosorbent assay. The effects of the promoter polymorphism rs11666254 on the transcription activity of FPR2/ALX were analyzed using a luciferase reporter assay.ResultsAmong the three tag SNPs, only the rs11666254 polymorphism was found to be significantly associated with sepsis in trauma patients, and this association persisted after a pooled analysis of all 646 trauma patients, which showed that patients who carried the A allele of rs11666254 had a significantly higher risk of developing sepsis than individuals who carried the G allele. This SNP was also significantly associated with lower FPR2/ALX mRNA and protein expression as well as higher TNF-α production from the peripheral blood leukocyte response to bacterial lipoprotein stimulation. In addition, the rs11666254 polymorphism could significantly decrease the promoter activity of the FPR2/ALX gene.ConclusionsThe rs11666254 polymorphism in the FPR2/ALX gene is a functional SNP that increases sepsis susceptibility in patients after traumatic injury.Electronic supplementary materialThe online version of this article (doi:10.1186/s13054-017-1757-3) contains supplementary material, which is available to authorized users.

Current gaps in sepsis immunology: new opportunities for translational research

“…Most available studies use the candidate gene approach dealing with, for example, cytokine genes that can affect the inflammatory response, genes encoding for patternrecognition receptors (like Toll-like receptors), or genes that shape the response to infections. 14,15 As such studies often suffer from poor reproducibility, an alternative could be conducting well planned and well powered data-driven genomic studies. Typically, these works are developed in consortia and lead to highly reproducible associations.…”

Host Lipid Mediators in Leprosy: The Hypothesized Contributions to Pathogenesis

“…Thus, studies that assess the presence of these receptors in the T cells of TT/BT and BL/LL patients are required to fully understand the potential influence of RvD1 on the adaptive immune response across the spectrum of leprosy. Polymorphisms in the promoter region of the ALX/FPR2 gene resulting in a reduced expression of this receptor are known ( 100 , 101 ). Thus, it would also be interesting to investigate whether polymorphisms exist between TT/BT and BL/LL patients in the promoter or functional regions of the GPR32 and ALX/FPR2 genes.…”

Roles of Specialized Pro-Resolving Lipid Mediators in Autophagy and Inflammation

“…In addition, in vitro studies showed that ALX/FPR2 is a promiscuous receptor that is also recognized and stimulated by a variety of natural and synthetic peptides to translate effects ranging from pro-inflammatory to anti-inflammatory and pro-resolution depending on the activating ligand (reviewed in [79]). However, the ALX/FPR2 transgenic and knock-out mouse models confirmed the crucial role of this receptor in inflammation resolution [80,81], and findings in human indicated that ALX/FPR2 levels dictate the amplitude of inflammation and its defective expression could be associated with inflammatory disorders [82,83].…”